根据《中华人民共和国药品管理法》《药品生产监督管理办法》《药品检查管理办法（试行）》《药品生产质量管理规范符合性检查工作程序》有关规定及 要求，我局对华东医药（西安）博华制药有限公司等7家药品生产企业进行药品生产质量管理规范符合性检查和审核，经现场检查并综合评定，现将检查结 果通告如下： | 受托方： 榆林利君 制药有限 | | | | | | --- | --- | --- | --- | --- | | 公司 | | | | | | 西安力邦 | 西安市未央 | | 2025年9 月16 | | | 制药有限 | 区六村堡工 | 原料药：右泛醇（二车间、三车间、净化二车间，右泛醇生产线） | 日-2025 | 符 | | 公司 | 业园丰产路 42号 | | 年9月19 | 合 | | | | | 日 | | | 西安力邦 | 西安市高新 | | 2025年9 月22 | | | 制药有限 | 区科技一路 | 前列地尔注射液（一车间，2线）、小容量注射剂（一车间，1线、2线） | 日-2025 | 符 | | 公司 | 22号 | | 年9月24 | 合 | | | | | 日 | | | | 辽宁省新民 ...

Core Insights - ST Sairong reported a significant decline in both revenue and net profit for 2024, indicating increased operational pressure due to market competition and policy adjustments in the pharmaceutical industry [1][3][5] Revenue and Profit Performance - The company's total revenue for 2024 was 264 million, a year-on-year decrease of 15.15% from 311 million in 2023 [1][3] - The net profit attributable to shareholders was -33 million, a drastic decline of 447.67% compared to the previous year [1][3] - The net profit after excluding non-recurring gains and losses was -33.5 million, reflecting a staggering drop of 1275.25% [1][3] R&D Investment and Outcomes - Despite increasing R&D investments, the conversion of these efforts into financial improvement has been limited [4] - The company received approval notifications for 12 raw materials, including hydrochloride esmolol and fluorouracil, and completed registrations for several injectable formulations [4] - The low efficiency in converting R&D outcomes into market competitiveness has exacerbated the company's financial burden [4] Market Competition and Sales Strategy - The pharmaceutical industry faced intensified competition in 2024, driven by policy changes and expanded centralized procurement [5] - ST Sairong adjusted its sales strategies to enhance market share and optimize product sales structure, but these efforts yielded limited results due to fierce competition [5] - Although sales and management expenses decreased, this reduction did not significantly improve net profit performance [5]